44 2033180199
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Clinical Pharmacology and Toxicology Research

Sign up for email alert when new content gets added: Sign up

Spinal Muscle Atrophy (Types l & ll & lll& lV): Literature Review

Author(s): El-Sayed M. Lashine , Ahmed S. El-Sayed , Ahmed K. Elshahat , Ahmed R. Zaki , Ahmed S. El-Halaby , Ahmed S. Mostafa , Ahmed K. Shabaan , Ahmed S. Sobhy , Ahmed S. Abd Alsamed , Ahmed S. El-attar , Ahmed S. Farrag1 , Mahmoud M. Sebaiy

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease characterized by degeneration of alpha motor neurons in the spinal cord, resulting in progressive proximal muscle weakness and paralysis. Estimated incidence is 1 in 6,000 to 1 in 10,000 live births and carrier frequency of 1/40 - 1/60. This disease is characterized by generalized muscle weakness and atrophy predominating in proximal limb muscles, and phenotype is classified into four grades of severity (SMA I, SMAII, SMAIII, SMA IV) based on age of onset and motor function achieved. This disease is caused by homozygous mutations of the survival motor neuron 1 (SMN1) gene, and the diagnostic test demonstrates in most patients the homozygous deletion of the SMN1 gene, generally showing the absence of SMN1 exon 7. The test achieves up to 95% sensitivity and nearly 100% specificity. Differential diagnosis should be considered with other neuromuscular disorders which are not associated with increased CK manifesting as infantile hypotonia or as limb girdle weakness starting later in life.


PDF
 
Google Scholar citation report
Citations : 13

Clinical Pharmacology and Toxicology Research received 13 citations as per Google Scholar report

Top